Frederic Amant, MD, PhD, of the Katholieke Universiteit Leuven, discusses the important decisions that must be made when a woman is diagnosed with cancer while pregnant: Should treatment be delayed or the pregnancy terminated?
Incoming ECCO President, Peter L. J. Naredi, MD, PhD, of the University of Gothenburg, discusses his upcoming year as the new ECCO President, his vision for the organization, and his views on cancer treatment today.
M. Catherine Pietanza, MD, of Memorial Sloan Kettering Cancer Center, discusses rovalpituzumab tesirine, a promising DLL3-targeted antibody drug conjugate, the first precision treatment for small cell lung cancer (Abstract 7LBA).
Tony Mok, MD, of The Chinese University of Hong Kong, and Alice Shaw, MD, PhD, of Massachusetts General Hospital, discuss the current status and future outlook of ALK inhibition, and an assessment of brigatinib CNS activity in patients with ALK-positive non-small cell lung cancer and intracranial metastases (Abstract 3061).
Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses the results of this study, which could well change the treatment paradigm in patients with previously treated metastatic renal cell carcinoma (Abstract 3LBA).
Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses the latest developments in an important cancer treatment avenue.
